Relay Therapeutics Inc.
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhan...
Latest News
5 days ago · globenewswire.com
Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report third quarter 2026 financial results and corporate highlights after the U.S. financial markets close on Wednesday, November 4, 2026.
2 months ago · seekingalpha.com
Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptRelay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
2 months ago · seekingalpha.com
Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks TranscriptRelay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript
2 months ago · fool.com
Relay Therapeutics CFO Sells 17,717 Shares for $350,000The sale had an approximate value of nearly $350,000. The transaction reduced the executive's direct equity position by 11%.
2 months ago · globenewswire.com
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in SeptemberCAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September:
3 months ago · zacks.com
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue EstimatesRelay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.41 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.41 per share a year ago.
3 months ago · globenewswire.com
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate UpdatesSelected z ovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine - sensitive patients expected to initiate in early 2027, subject to regulatory feedback
3 months ago · globenewswire.com
Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report second quarter 2026 financial results and corporate highlights after the U.S. financial markets close on Thursday, August 6, 2026.
3 months ago · zacks.com
Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?Relay Therapeutics (RLAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 months ago · fool.com
Relay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past YearThomas Catinazzo sold 187,163 shares of Common Stock for $3.18 million on June 22, 2026, at a weighted average price of around $16.97 per share. This transaction reduced his direct Common Stock holdings by 51.33%, leaving 177,461 shares directly held after the sale.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove RLAY